Literature DB >> 18625430

Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

Vincent Lo Re1, Jay R Kostman, Valerianna K Amorosa.   

Abstract

Because of shared routes of transmission, hepatitis C virus (HCV) coinfection is common among HIV-infected persons. Because of the effectiveness of antiretroviral therapy, chronic HCV has now emerged as a major cause of morbidity and mortality in this population. Because chronic HCV is highly prevalent among HIV-infected patients and has a rapid disease progression, antiviral therapy with pegylated interferon plus ribavirin is critical for the long-term survival of HIV/HCV-coinfected patients. In this article, the authors review the (1) epidemiology of HCV among HIV-infected individuals, (2) effect of HIV on the natural history of chronic HCV, (3) impact of antiretroviral therapy on HCV coinfection, and (4) management of chronic HCV in the HIV-infected person.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18625430      PMCID: PMC2593801          DOI: 10.1016/j.cld.2008.03.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  137 in total

1.  Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy.

Authors:  Vincent Lo Re; Jay R Kostman; Robert Gross; K Rajender Reddy; Karam Mounzer; Babette S Zemel; Hanna Rennert; Donald D Stieritz; Mary Putt; Ian Frank; Brian L Strom
Journal:  J Acquir Immune Defic Syndr       Date:  2007-03-01       Impact factor: 3.731

Review 2.  Anemia during treatment of hepatitis C in HIV-infected patients.

Authors:  Vincent Lo Re; Jay R Kostman
Journal:  AIDS Read       Date:  2004-10

3.  Hepatitis C virus infection in patients infected with the human immunodeficiency virus.

Authors:  C M Quan; M Krajden; G A Grigoriew; I E Salit
Journal:  Clin Infect Dis       Date:  1993-07       Impact factor: 9.079

4.  Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy.

Authors:  Stefan Mauss; William Valenti; Jean DePamphilis; Frank Duff; Lisa Cupelli; Sharon Passe; Jonathan Solsky; Francesca J Torriani; Douglas Dieterich; Dominique Larrey
Journal:  AIDS       Date:  2004-09-03       Impact factor: 4.177

5.  Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study.

Authors:  M E Eyster; L S Diamondstone; J M Lien; W C Ehmann; S Quan; J J Goedert
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1993-06

6.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

7.  Acute hepatitis C in HIV-infected men who have sex with men.

Authors:  J Ghosn; S Pierre-François; V Thibault; C Duvivier; R Tubiana; A Simon; M A Valantin; S Dominguez; E Caumes; C Katlama
Journal:  HIV Med       Date:  2004-07       Impact factor: 3.180

8.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.

Authors:  Francesca J Torriani; Maribel Rodriguez-Torres; Jürgen K Rockstroh; Eduardo Lissen; Juan Gonzalez-García; Adriano Lazzarin; Giampiero Carosi; Joseph Sasadeusz; Christine Katlama; Julio Montaner; Hoel Sette; Sharon Passe; Jean De Pamphilis; Frank Duff; Uschi Marion Schrenk; Douglas T Dieterich
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

9.  Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons.

Authors:  Raymond T Chung; Janet Andersen; Paul Volberding; Gregory K Robbins; Tun Liu; Kenneth E Sherman; Marion G Peters; Margaret J Koziel; Atul K Bhan; Beverly Alston; Dodi Colquhoun; Tom Nevin; George Harb; Charles van der Horst
Journal:  N Engl J Med       Date:  2004-07-29       Impact factor: 91.245

10.  Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay.

Authors:  P Marcellin; M Martinot-Peignoux; A Elias; M Branger; F Courtois; R Level; S Erlinger; J P Benhamou
Journal:  J Infect Dis       Date:  1994-08       Impact factor: 5.226

View more
  10 in total

1.  Alterations in immune function are associated with liver enzyme elevation in HIV and HCV co-infection after commencement of combination antiretroviral therapy.

Authors:  Barbara Anne Cameron; Carol R Emerson; Cassy Workman; Mark D Kelly; Andrew R Lloyd; Jeffrey J Post
Journal:  J Clin Immunol       Date:  2011-09-20       Impact factor: 8.317

2.  Hepatitis C treatment experiences and decision making among patients living with HIV infection.

Authors:  Carol Bova; Lisa Fink Ogawa; Susan Sullivan-Bolyai
Journal:  J Assoc Nurses AIDS Care       Date:  2009-10-22       Impact factor: 1.354

3.  RNA interference effectively degrades mRNA and inhibits protein expression of GBV-C E2 gene in Huh7 cells.

Authors:  Ming-Mei Cao; Gang Li; Hao Ren; Wei Pan; Ping Zhao; Zhong-Tian Qi
Journal:  Virus Genes       Date:  2009-10-03       Impact factor: 2.332

4.  New frontiers of HCV therapy in HIV/HCV co-infection.

Authors:  Valerianna K Amorosa
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.495

5.  Results of antiretroviral treatment interruption and intensification in advanced multi-drug resistant HIV infection from the OPTIMA trial.

Authors:  Mark Holodniy; Sheldon T Brown; D William Cameron; Tassos C Kyriakides; Brian Angus; Abdel Babiker; Joel Singer; Douglas K Owens; Aslam Anis; Ruth Goodall; Fleur Hudson; Mirek Piaseczny; John Russo; Martin Schechter; Lawrence Deyton; Janet Darbyshire
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

6.  Determinants of stigma among patients with hepatitis C virus infection.

Authors:  M Elle Saine; Julia E Szymczak; Tyler M Moore; Laura P Bamford; Frances K Barg; Jason Schnittker; John H Holmes; Nandita Mitra; Vincent Lo Re
Journal:  J Viral Hepat       Date:  2020-06-23       Impact factor: 3.517

7.  Association between IL7R polymorphisms and severe liver disease in HIV/HCV coinfected patients: a cross-sectional study.

Authors:  María Guzmán-Fulgencio; Juan Berenguer; María A Jiménez-Sousa; Daniel Pineda-Tenor; Teresa Aldámiz-Echevarria; Pilar García-Broncano; Ana Carrero; Mónica García-Álvarez; Francisco Tejerina; Cristina Diez; Sonia Vazquez-Morón; Salvador Resino
Journal:  J Transl Med       Date:  2015-06-30       Impact factor: 5.531

Review 8.  The next therapeutic challenge in HIV: polypharmacy.

Authors:  E Jennifer Edelman; Kirsha S Gordon; Janis Glover; Ian R McNicholl; David A Fiellin; Amy C Justice
Journal:  Drugs Aging       Date:  2013-08       Impact factor: 3.923

9.  FTO rs9939609 polymorphism is associated with metabolic disturbances and response to HCV therapy in HIV/HCV-coinfected patients.

Authors:  Daniel Pineda-Tenor; Juan Berenguer; María A Jiménez-Sousa; Mónica García-Alvarez; Teresa Aldámiz-Echevarria; Ana Carrero; Sonia Vázquez-Morón; Pilar García-Broncano; Cristina Diez; Francisco Tejerina; María Guzmán-Fulgencio; Salvador Resino
Journal:  BMC Med       Date:  2014-11-03       Impact factor: 8.775

10.  Mortality of patients infected with HIV in the intensive care unit (2005 through 2010): significant role of chronic hepatitis C and severe sepsis.

Authors:  José Medrano; Alejando Álvaro-Meca; Alexandre Boyer; María A Jiménez-Sousa; Salvador Resino
Journal:  Crit Care       Date:  2014-08-27       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.